Drugs / 13C-Methacetin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02786836 | Jun 2016 → Sep 2019 | acute liver failure | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01785082 | Jan 2013 → Sep 2015 | liver failure | Humedics GmbH | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00244569 Background | Sep 2005 → Apr 2007 | cirrhosis of liver, fatty liver disease | Virginia Commonwealth University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-11-05 | Galectin Therapeutics Inc. | Results Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting galectintherapeutics.com ↗
The study showed that MBT, which measures liver function, strongly predicts liver decompensation in patients with compensated NASH cirrhosis. |
| 2018-05-11 | Galectin Therapeutics Inc. | Results Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update galectintherapeutics.com ↗
Finally, results from the 13C-Methacetin Breath Test, a measure of liver function, conducted as part of the trial found that results for patients without baseline varices mirrored the results for changes in HVPG. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-11-05 | Galectin Therapeutics Inc. | Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting galectintherapeutics.com ↗ |
| 2018-05-11 | Galectin Therapeutics Inc. | Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update galectintherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-C-Methacetin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01785082 ↗ |
| Modality | Diagnostic / imaging agent | “The 13C-Methacetin breath test is a rapid, reproducible, point-of-care test of liver metabolic function.” NCT02786836 ↗ |
| Route | Oral | “the 13C-compound would be administered orally, rapidly absorbed, metabolized by the liver” NCT00244569 ↗ |